Directed share issue, January 2019
Share issue, September 2018
Prospectus in summary
Directed share issue, March 2017
Link to pressrelease
Rights issue in connection with listing on Nasdaq First North, December 2015
The rights issue of SEK 19.5 million, which was carried out prior to the admission to trading of Vicore Pharma’s shares on Nasdaq First North, was subscribed to 178 percent, of which 75 percent was subscribed with the support of subscription rights and 104 percent without the support of subscription rights. The great interest meant that the Board decided to utilize the entire over-allotment option of SEK 6.0 million, which meant that the company was allocated SEK 25.5 million before transaction costs.
In the issue, 3 248 144 shares were issued and in the over-allotment option an additional 1,000,000 shares were issued. In total, 4 248 144 shares were issued at a price of SEK 6.00.